Mode
Text Size
Log in / Sign up
Phase 4 Completed N=24 Randomized Treatment

Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension

Source: ClinicalTrials.gov NCT01519635 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide — 20.5; 19.5; 19.5; 20.5 1/sec
◆ Published Evidence
Emerging
12citations · ~1 / year
Comparative Effect of a Renin Inhibitor and a Thiazide Diuretic on Renal Tissue Oxygenation in Hypertensive Patients.
Kidney & blood pressure research · 2015 · Open access · High-confidence link

Summary

The goal of this project is to evaluate the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension, and to compare the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension with these effects with those of ESIDREX 25mg (hydrochlorothiazide).

Linked Publications

  • Comparative Effect of a Renin Inhibitor and a Thiazide Diuretic on Renal Tissue Oxygenation in Hypertensive Patients.
    Kidney & blood pressure research · 2015 · 12 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide
20.5; 19.5; 19.5; 20.5

Eligibility Criteria

Inclusion Criteria

  • Tolerance to study drugs
  • Age > 18 years
  • Arteria hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg)
  • Normal renal function
  • Availability to give informed consent

Exclusion Criteria

  • Intolerance to study drugs
  • Renal artery stenosis
  • Hyperkalaemia > 5.0 mmol/l
  • Contra-indications to the use of PAH, inulin or Lithium
  • Asthma
  • Pychiatric illness
  • No estimated easy vascular venous access for placement of two peripherical venous catheters in forearms
  • Contra-indication to MRI-imaging: Claustrophobia or Pacemaker or other implanted metal device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01519635) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search